$11.49
1.59% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Roivant Sciences Stock price

$11.49
-0.13 1.12% 1M
+0.12 1.06% 6M
+0.26 2.32% YTD
+2.69 30.57% 1Y
+3.62 46.00% 3Y
+2.14 22.89% 5Y
+2.14 22.89% 10Y
Nasdaq, Closing price Wed, Nov 20 2024
+0.18 1.59%
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Key metrics

Market capitalization $8.36b
Enterprise Value $3.45b
P/E (TTM) P/E ratio 2.03
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 27.48
P/S ratio (TTM) P/S ratio 66.55
P/B ratio (TTM) P/B ratio 1.64
Revenue growth (TTM) Revenue growth 21.84%
Revenue (TTM) Revenue $125.68m
EBIT (operating result TTM) EBIT $-1.13b
Free Cash Flow (TTM) Free Cash Flow $-781.21m
Cash position $5.39b
EPS (TTM) EPS $5.66
P/E forward negative
P/S forward 82.79
EV/Sales forward 34.19
Short interest 8.35%
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Roivant Sciences forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Roivant Sciences forecast:

Buy
91%
Hold
9%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
126 126
22% 22%
100%
- Direct Costs 21 21
42% 42%
16%
121 121
77% 77%
96%
- Selling and Administrative Expenses 711 711
26% 26%
566%
- Research and Development Expense 520 520
1% 1%
414%
-1,115 -1,115
10% 10%
-887%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -1,126 -1,126
8% 8%
-896%
Net Profit 4,810 4,810
590% 590%
3,827%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Neutral
Seeking Alpha
9 days ago
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimmer - Chief Executive Officer, Priovant Conference Call Participants Louise Chen - Cantor Brian Cheng - JPMorgan Joyce Zhou - TD Cowen Andy Chen - Wolfe Research Douglas Tsao - H.C.
Neutral
GlobeNewsWire
23 days ago
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update.
Neutral
GlobeNewsWire
24 days ago
The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 908
Founded 2014
Website www.roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today